Clinical trial NCT06513221: A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
Official title: A Prospective, Multi-arm, Phase II Clinical Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab Under the Guidance of Transcriptome Profiling.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Metastatic Colorectal Cancer
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective, multi-arm, phase II clinical trial that uses transcriptome profiling to guide the evaluation of the efficacy of multiple lines of standard chemotherapy and bevacizumab combined with adebrelimab in patients with MSS-type metastatic colorectal cancer, aiming to expand the immunotherapy cohort while accurately narrowing the population of MSS-type colorectal cancer that benefits from immunity. This study includes a screening period, a treatment period, and a follow-up period.

Detailed description: This study plans to include a total of 100 first-line, second-line, and third-line MCRIH (MSS Colorectal Cancer Immuno-Hot) participants. First-line and second-line participants who pass the screening period will receive standard chemotherapy (XELOX/mXELIRI: conventional dose) combined with Bevacizumab (7.5mg/kg, q3w) and Adebrelimab (1200mg, q3w); third-line subjects will receive Fruquintinib (4mg po d1\~d14, q3w) combined with Adebrelimab (1200mg, q3w). Participants will receive imaging examinations during the treatment period to evaluate efficacy and progression. In addition, any adverse reactions at any time will be recoded to evaluate safety. The EDC system will be used to collect statistics on participants examination data.

Eligibility criteria: Inclusion Criteria:

1. Voluntary participation and written informed consent
2. Aged 18 years and above, regardless of gender;
3. Histologically confirmed, resectable primary lesions, unresectable metastatic lesions, MSS-type mCRC
4. MCRIH by transcriptome typing;
5. At least one measurable lesion diagnosed by imaging, according to the solid tumor response evaluation criteria (RECIST1.1);
6. Estimated survival ≥ 3 months;
7. ECOG score 0-1 points;
8. Adequate organ and bone marrow function:

   Neutrophil count: ≥1.5\*10\^9/L Platelet count: ≥10.0\*10\^9/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤ 1.5 ULN AST, ALT: ≤ 2.5 \*ULN (or \<5\*ULN in case of liver metastasis) Serum creatinine: 1.25 \*ULN
9. Male subjects and women of childbearing age must take contraceptive measures from the first dose to 3 months after the last dose;
10. It is expected that the patient will have good compliance and can cooperate with the study as required by the protocol;

Exclusion Criteria:

1. Known allergy to the study drug or any of its excipients;
2. Previous treatment with immune checkpoint inhibitors;
3. Received the following treatments or drugs before the first study treatment:

   * Major surgery within 28 days before treatment (tissue biopsy for diagnostic purposes is allowed).
   * Use of immunosuppressive drugs within 7 days before treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (i.e. no more than 10 mg/d of prednisone or other corticosteroids of equivalent physiological dose);
   * Received immunomodulatory drugs (such as thymosin, interferon, interleukin) within 3 weeks before medication;
   * Received live attenuated vaccines within 28 days before treatment;
   * Received other anti-tumor systemic treatment within 28 days before treatment;
4. Presence of any active autoimmune disease or history of autoimmune disease and expected recurrence;
5. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
6. Human immunodeficiency virus (HIV) infection or known AIDS, untreated active hepatitis, HBV-DNA ≥ 2500 IU/ml and abnormal liver function; hepatitis C or co-infection with hepatitis B and hepatitis C;
7. Within 6 months before entering the study, the following conditions occurred: myocardial infarction, severe/unstable angina, NYHA Patients with grade 2 or above heart failure and clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention; hypertension that is poorly controlled by drugs;
8. History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months before the first study treatment;
9. Urine protein ≥++ or 24-hour urine protein \> 1.0g;
10. Unable to swallow the study drug, with multiple factors that affect drug administration and absorption, such as chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction;
11. Pregnant or lactating women, and subjects with reproductive capacity who are unwilling to take effective contraceptive measures;
12. Patients with other serious physical or laboratory abnormalities that may increase the risk of participating in the study or interfere with the study results, and patients who are considered unsuitable for participation in this study by the investigator;

Primary outcomes:
measure: Objective Response Rate
timeFrame: 2 years
Secondary outcomes:
measure: Disease Control Rate
timeFrame: 2 years
measure: Progression Free Survival
timeFrame: 2 years
measure: Overall Survical
timeFrame: 2 years
measure: QoL
timeFrame: 2 years
measure: Incidence of Treatment-related Adverse Events (Safety )
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
References: